MDACC Study No:2010-0981 ( NCT No: NCT01409161)
Title:Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) with ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Arsenic Trioxide; ATRA; Gemtuzamab Ozogamicin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab
ozogamicin (GO) can help to control APL. The safety of this drug combination
will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Arsenic Trioxide
Gemtuzamab Ozogamicin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pfizer, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults